Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.59 |
| ▸ | RARG | P13631 | 12/20 | 0.59 |
| ▸ | RARA | P10276 | 11/20 | 0.59 |
| ▸ | RXRA | P19793 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717570 | 0.87 | RARB (0.46) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL7217366 | 0.84 | RARA (0.55) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL7714814 | 0.80 | RARB (0.62) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL19034092 | 0.79 | RARA (0.51) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL6017426 | 0.78 | RARA (0.47) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL10976930 | 0.78 | RARB (0.76) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL10976941 | 0.78 | RARB (0.76) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL180442 | 0.78 | CYP3A4 (0.70) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL8293245 | 0.76 | RARA (0.47) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL3838099 | 0.75 | RARB (0.57) | RARBRARGRARARXRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-0740665-B1 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | ALLERGAN SALES INC (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0661258-B1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CIRD GALDERMA (FR) | 1998-04-08 | — | — | EP | disclosed |
| US-5716624-A | USEFUL FOR TREATING DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, OPTHALMOLOGICAL DISORDERS, AS WELL AS MAMMALIAN SKIN AND HAIR CONDITIONS/DISORDERS | C.I.R.D. GALDERMA (FR) | 1998-02-10 | — | — | US | disclosed |
| EP-0740665-A1 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | Allergan (US) | 1996-11-06 | — | — | EP | disclosed |
| US-5519150-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN (US) | 1996-05-21 | — | — | US | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995019973-A2 | PROCESS FOR PREPARING 4,4-DIALKYL-6-HALO-CHROMANS OR THIOCHROMANS USEFUL AS PHARMACEUTICAL INTERMEDIATES | ALLERGAN (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0661258-A1 | Biaromatic propynyl compounds, pharmaceutical compositions and cosmetics containing them and their uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
| US-5420295-A | Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates | ALLERGAN, INC. (US) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | RARB 2563/4885RARG 3101/4885RARA 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.